Answers are grounded in this paper and cite their sources.
Introduction: Aprepitant is a chiral prodrug possessing three stereogenic centers and exists in eight stereochemical forms. It was aimed to estimate and validate Aprepitant using reverse phase HPLC. Materials and methods: Chiral liquid chromatography with an ion-trap mass spectrophotometer was used to isolate all the isomers. The separation of the eight isomers was achieved on an amylase-based chiral column (Chiralpak ADH, 250 mm � 4.6 mm) using n-hexane/isopropyl alcohol/methanol/trifluoroacetic acid (970/40/4/0.5, vol/vol/vol/vol) as the mobile phase at a flow rate of 0.5 ml/min. A reverse-phase HPLC method was used to analyze Aprepitant and its related substances. The determination of Aprepitant and its related substances was developed by using Xterra RP e 18, 250 mm � 4.6 mm, 5 mm column. Results and conclusion: These methods were validated according to the International Conference on Harmonization (ICH) guidelines. The limit of detection (LOD) and limit of quantitation (LOQ) for Aprepitant were found to be 0.14 mg/ml and 0.41 mg/ml, respectively, for chiral substance and 0.07 mg/ml and 0.21 mg/ml, respectively, for the related substance.
No takes yet. Share an insight, caveat, or question.
Sinha et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: